Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Purchased by Calamos Advisors LLC

Calamos Advisors LLC lifted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 10.5% during the fourth quarter, Holdings Channel reports. The fund owned 326,629 shares of the medical equipment provider’s stock after buying an additional 30,908 shares during the quarter. Calamos Advisors LLC’s holdings in Zimmer Biomet were worth $39,751,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Clear Street Markets LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter worth $27,000. Lazard Asset Management LLC boosted its holdings in Zimmer Biomet by 70.5% during the third quarter. Lazard Asset Management LLC now owns 283 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 117 shares in the last quarter. Dark Forest Capital Management LP purchased a new stake in Zimmer Biomet during the first quarter worth $35,000. Activest Wealth Management boosted its holdings in Zimmer Biomet by 410.4% during the fourth quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 275 shares in the last quarter. Finally, Peoples Bank KS purchased a new stake in Zimmer Biomet during the third quarter worth $48,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Trading Down 1.6 %

Shares of NYSE ZBH traded down $1.97 on Thursday, reaching $119.33. 1,442,170 shares of the company traded hands, compared to its average volume of 1,483,552. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $102.00 and a fifty-two week high of $149.25. The company has a 50 day moving average of $126.47 and a 200 day moving average of $119.10. The company has a current ratio of 1.61, a quick ratio of 0.78 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $24.52 billion, a PE ratio of 24.81, a P/E/G ratio of 2.24 and a beta of 1.01.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, beating analysts’ consensus estimates of $2.15 by $0.05. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. The company had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.93 billion. During the same quarter in the prior year, the company posted $1.88 EPS. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. On average, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.80%. The ex-dividend date is Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio is currently 19.63%.

Insider Buying and Selling

In related news, VP Chad F. Phipps sold 26,156 shares of the stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the completion of the sale, the vice president now owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.95% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on ZBH shares. TheStreet raised shares of Zimmer Biomet from a “c” rating to a “b-” rating in a report on Thursday, February 8th. Canaccord Genuity Group reissued a “hold” rating and set a $130.00 price target on shares of Zimmer Biomet in a report on Friday, February 23rd. JPMorgan Chase & Co. increased their price target on shares of Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a report on Friday, February 9th. Raymond James increased their price target on shares of Zimmer Biomet from $133.00 to $137.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Finally, Citigroup increased their price objective on shares of Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a report on Wednesday, April 3rd. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and an average target price of $139.39.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.